Hyperion DeFi (HYPD) Stock Price, News & Analysis

Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Key Stats

• Today's Range: $5.99 to $6.92
• 50-Day Range: $2.44 to $15.97
• 52-Week Range: $0.85 to $75.18
• Volume: 348,479 shs
• Average Volume: 2.10 million shs
• Market Capitalization: $36.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Hold

Hyperion DeFi Stock Analysis - MarketRank™

Hyperion DeFi scored higher than 6% of companies evaluated by MarketBeat, and ranked 919th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Hyperion DeFi has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Hyperion DeFi has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Hyperion DeFi are expected to grow in the coming year, from ($41.60) to ($16.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hyperion DeFi is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hyperion DeFi is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HYPD.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hyperion DeFi does not currently pay a dividend.

Dividend Growth

Hyperion DeFi does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for HYPD.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.29

News Sentiment

Hyperion DeFi has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Hyperion DeFi this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for HYPD on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

6 people have added Hyperion DeFi to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hyperion DeFi insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.86% of the stock of Hyperion DeFi is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 25.84% of the stock of Hyperion DeFi is held by institutions.

HYPD Stock Analysis - Frequently Asked Questions

How have HYPD shares performed this year?

Hyperion DeFi's stock was trading at $11.68 at the beginning of 2025. Since then, HYPD shares have decreased by 44.9% and is now trading at $6.44.

How were Hyperion DeFi's earnings last quarter?

Hyperion DeFi, Inc. (NASDAQ:HYPD) issued its quarterly earnings results on Wednesday, August, 13th. The company reported ($2.50) EPS for the quarter.

When did Hyperion DeFi's stock split?

Hyperion DeFi shares reverse split on the morning of Monday, February 3rd 2025.The 1-80 reverse split was announced on Tuesday, January 28th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Hyperion DeFi?

Shares of HYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HYPD
• Previous Symbol: NASDAQ:EYEN
• CIK: 1682639
• Web: www.eyenovia.com
• Phone: (917) 289-1117
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Hyperion DeFi: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: -71.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($58.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.82 million
• Net Margins: -62,238.41%
• Pretax Margin: -62,238.41%
• Return on Equity: N/A
• Return on Assets: -316.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.34
• Quick Ratio: 0.34

Sales & Book Value

• Annual Sales: $67.06 thousand
• Price / Sales: 588.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($695.52) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 5,603,000
• Free Float: 4,995,000
• Market Cap: $39.45 million
• Optionable: Optionable
• Beta: 2.42